Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Physiometrix PSA 4000

This article was originally published in The Gray Sheet

Executive Summary

Anesthesia monitoring system gains 510(k) clearance for observing and controlling a patient's degree of consciousness during surgery, the firm announces July 5. Exclusive distribution partner Baxter is expected to begin shipments of the device in August

You may also be interested in...



Aspect BIS “Awareness” Indication Supported By Three Studies

An expanded indication for Aspect Medical's BIS bispectral index anesthesia monitoring technology for "reducing the risk of intraoperative awareness with recall" will be a competitive advantage, although the impact on sales remains undetermined, the firm says

Lack Of Industry Involvement In Scoping Process Exacerbates ‘Unworkable’ Timelines

Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT013604

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel